Recommendations on European data protection certification

The objective of this report is to identify and analyse challenges and opportunities of data protection certification mechanisms, including seals and marks, as introduced by the GDPR, focusing also on existing initiatives and voluntary schemes

Redress for dark patterns privacy harms?:A case study on consent interactions

nternet users are constantly subjected to incessant demands for attention in a noisy digital world. Countless inputs compete for the chance to be clicked, to be seen, and to be interacted with, and they can deploy tactics that take advantage of behavioral psychology to 'nudge' users into doing what they want. Some nudges are benign; others deceive, steer, or manipulate users, as the U.S. FTC Commissioner says, "into behavior that is profitable for an online service, but often harmful to [us] or contrary to [our] intent". These tactics are dark patterns, which are manipulative and deceptive interface designs used at-scale in more than ten percent of global shopping websites and more than ninety-five percent of the most popular apps in online services. Literature discusses several types of harms caused by dark patterns that includes harms of a material nature, such as financial harms, or anticompetitive issues, as well as harms of a non-material nature, such as privacy invasion, time loss, addiction, cognitive burdens, loss of autonomy, and emotional or psychological distress. Through a comprehensive literature review of this scholarship and case law analysis conducted by our interdisciplinary team of HCI and legal scholars, this paper investigates whether harms caused by such dark patterns could give rise to redress for individuals subject to dark pattern practices using consent interactions and the GDPR consent requirements as a case study

Factors associated with under-5 mortality in three disadvantaged East African districts

BACKGROUND: The high rate of avoidable child mortality in disadvantaged communities in Africa is an important health problem. This article examines factors associated with mortality in children 6 h away from the nearest health centre (6-23 h: AOR 1.66 [95% CI 1.4-2.0] and ?24 h: AOR 1.43 [95% CI 1.26-1.72]) reported higher mortality rates in children 6 h away from health centres and mothers who received inadequate ANC visits during pregnancy

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention